These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 23188444

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.
    Poller DN, Silverstein MJ, Galea M, Locker AP, Elston CW, Blamey RW, Ellis IO.
    Mod Pathol; 1994 Feb; 7(2):257-62. PubMed ID: 7911998
    [Abstract] [Full Text] [Related]

  • 3. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK, Tjan S, Parkes RK, O'Malley FP.
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [Abstract] [Full Text] [Related]

  • 4. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.
    Daoud SA, Ismail WM, Abdelhamid MS, Nabil TM, Daoud SA.
    Asian Pac J Cancer Prev; 2016 Dec; 17(8):3733-6. PubMed ID: 27644608
    [Abstract] [Full Text] [Related]

  • 5. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
    Xu R, Perle MA, Inghirami G, Chan W, Delgado Y, Feiner H.
    Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
    [Abstract] [Full Text] [Related]

  • 6. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S, Wang J, Bourne P, Yang Q, Tang P.
    Ann Clin Lab Sci; 2007 Feb; 37(2):127-34. PubMed ID: 17522367
    [Abstract] [Full Text] [Related]

  • 7. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B.
    Anticancer Res; 2005 Feb; 25(3A):1719-23. PubMed ID: 16033090
    [Abstract] [Full Text] [Related]

  • 8. Distribution of myofibroblast cells and microvessels around invasive ductal carcinoma of the breast and comparing with the adjacent range of their normal-to-DCIS zones.
    Dabiri S, Talebi A, Shahryari J, Meymandi MS, Safizadeh H.
    Arch Iran Med; 2013 Feb; 16(2):93-9. PubMed ID: 23360631
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
    Recăreanu F, Simionescu C, Georgescu CV, Pirici E.
    Rom J Morphol Embryol; 2011 Feb; 52(3 Suppl):1059-64. PubMed ID: 22119825
    [Abstract] [Full Text] [Related]

  • 13. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
    Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ.
    Clin Cancer Res; 2005 Mar 15; 11(6):2163-8. PubMed ID: 15788662
    [Abstract] [Full Text] [Related]

  • 14. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
    Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA.
    Cancer Res; 2002 Mar 15; 62(6):1676-81. PubMed ID: 11912139
    [Abstract] [Full Text] [Related]

  • 15. Is there a low-grade precursor pathway in breast cancer?
    King TA, Sakr RA, Muhsen S, Andrade VP, Giri D, Van Zee KJ, Morrow M.
    Ann Surg Oncol; 2012 Apr 15; 19(4):1115-21. PubMed ID: 21935747
    [Abstract] [Full Text] [Related]

  • 16. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade.
    Mommers EC, Leonhart AM, Falix F, Michalides R, Meijer CJ, Baak JP, Diest PJ.
    J Pathol; 2001 Jul 15; 194(3):327-33. PubMed ID: 11439365
    [Abstract] [Full Text] [Related]

  • 17. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue.
    Lindemann K, Resau J, Nährig J, Kort E, Leeser B, Annecke K, Welk A, Schäfer J, Vande Woude GF, Lengyel E, Harbeck N.
    Histopathology; 2007 Jul 15; 51(1):54-62. PubMed ID: 17593080
    [Abstract] [Full Text] [Related]

  • 18. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
    Perrone G, Santini D, Vincenzi B, Zagami M, La Cesa A, Bianchi A, Altomare V, Primavera A, Battista C, Vetrani A, Tonini G, Rabitti C.
    Histopathology; 2005 May 15; 46(5):561-8. PubMed ID: 15842638
    [Abstract] [Full Text] [Related]

  • 19. Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumour suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast.
    Sharma BK, Ray A, Kaur S, Gupta S.
    Indian J Exp Biol; 1999 Mar 15; 37(3):223-7. PubMed ID: 10641149
    [Abstract] [Full Text] [Related]

  • 20. Microvessel density and distribution in ductal carcinoma in situ of the breast.
    Guidi AJ, Fischer L, Harris JR, Schnitt SJ.
    J Natl Cancer Inst; 1994 Apr 20; 86(8):614-9. PubMed ID: 7511693
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.